The latest Phase 3 clinical data for Eli Lilly's next-generation weight-loss drug, retatrutide (RETA), has sent shockwaves through the scientific and financial communities. Participants achieved an average maximum weight loss of up to 28% of their body weight, approximately 70 pounds. Nearly half of the patients lost over 30% of their weight, with some severely obese patients averaging a staggering 85-pound loss over 104 weeks. This level of efficacy now squarely places the drug's performance within the range previously exclusive to bariatric surgery.
Independent medical experts not involved in the trial have called these results "the largest magnitude of weight loss ever seen in any drug trial." Eli Lilly announced it plans to submit RETA for regulatory approval to the U.S. Food and Drug Administration (FDA) as early as this year. Following the news, Eli Lilly's stock price continued its upward trajectory, pushing the company's market capitalization closer to the $1 trillion mark.
The emergence of RETA not only signifies a new evolutionary stage for GLP-1 class drugs but is also viewed by the market as a systemic shock to the "overconsumption economy." Stock prices across multiple sectors—from restaurants and fast food to alcohol and processed foods—have already come under pressure. Some medical professionals have even predicted:
"Within a few years, obesity will become a rare disease again."
RETA Clinical Data: Weight Loss Efficacy Comparable to Surgery The core breakthrough of RETA lies in its "triple agonist" mechanism. Unlike previous GLP-1 drugs, RETA simultaneously targets three metabolic pathways: GLP-1, GIP, and glucagon. In contrast, Eli Lilly's current blockbuster, Zepbound, is a dual agonist targeting only GLP-1 and GIP.
The reported Phase 3 trial involved approximately 2,300 obese or overweight patients over an 80-week period. Results showed that patients receiving the highest dose achieved an average weight loss of 28%, or about 70 pounds, with nearly half of those patients losing over 30% of their body weight. A subgroup of severely obese patients who extended treatment to 104 weeks achieved an average weight loss of 85 pounds.
For context, Zepbound's highest dose group achieved an average weight loss of about 21% over 72 weeks in its trial, while Wegovy's highest dose group showed about 15% average weight loss over 68 weeks in its separate study. It is important to note that these figures come from independent clinical trials.
Bariatric surgery typically helps patients lose 25% to 35% of their body weight within one to two years. RETA's data significantly overlaps with this range, leading several experts to label it a "game-changer."
Dr. Susan Spratt, an endocrinologist and senior medical director at Duke University Health System's Population Health Management Office, stated:
"This is the largest magnitude of weight loss I've ever seen in a drug trial. It's hugely significant."
Addressing Gaps in Current GLP-1 Efficacy RETA's clinical value extends beyond setting new weight loss records; it also holds potential for patients who do not respond adequately to existing GLP-1 medications.
Dr. Shauna Levy, Medical Director of the Tulane Bariatric Center, noted that current GLP-1 drugs often provide insufficient weight loss for patients with a BMI of 35 or higher (severe obesity).
"Bariatric surgery can provide sufficient weight loss, but RETA also looks like it will be an effective tool to help high-BMI patients reach a healthy weight."
Dr. Spratt added that approximately 10% of patients do not respond to current GLP-1 drugs, for whom RETA could be particularly valuable. "For GLP-1 non-responders, this drug could be very useful."
Regarding side effects, RETA's profile is similar to other GLP-1 drugs, with common issues including nausea, constipation, and diarrhea. Eli Lilly also disclosed that, compared to the placebo group, a higher proportion of RETA patients reported abnormal skin sensations and urinary tract infections. The trial's dropout rate was higher than that for Zepbound but similar to Wegovy.
Eli Lilly has not yet submitted RETA for FDA approval but indicated it could initiate the application process as early as this year.
Beyond Weight Loss: GLP-1 as a "Master Metabolic Switch" The advent of RETA is prompting the market to reassess the strategic value of the entire GLP-1 drug class, whose impact now extends far beyond simple weight reduction.
Existing research shows positive signals for GLP-1 drugs in reducing heart disease risk, improving sleep apnea, protecting kidney function, and reducing addictive behaviors. A new potential breakthrough is emerging in oncology:
The Cleveland Clinic is set to present data at a major global cancer conference. Tracking over 10,000 cancer patients, researchers found that GLP-1 users experienced a 38% to 50% reduction in tumor progression rates across various cancer types, including breast, lung, colon, and liver cancers. The researchers emphasized that this data is still in the early stages.
In drug development, the pharmaceutical industry is moving from dual agonists to competition involving triple, quadruple, and even quintuple agonists that target multiple metabolic pathways simultaneously. Some observers suggest the race to develop obesity drugs has evolved into an "arms race" targeting human metabolic mechanisms.
Medical professional Dr. Danish offered a striking prediction: "Within a few years, obesity will be viewed as a rare disease again."
Eli Lilly Nears Trillion-Dollar Valuation as Consumer Sectors Feel Pressure Simultaneously, the wave of RETA data is creating clear structural shifts in capital markets.
Eli Lilly's stock continues to benefit from RETA's prospects, driving toward all-time highs and the $1 trillion market cap threshold. Concurrently, assets under management by the Eli Lilly Foundation are approaching $100 billion. However, the rise of GLP-1 drugs poses a direct challenge to multiple consumer industries.
According to Deutsche Bank survey data, after starting medication, the proportion of patients dining at restaurants plummeted from 55% to 31%. Visits to fast-food outlets and cafes dropped from two-thirds to 37%. The frequency of ordering takeout and consuming alcohol also fell from over half to about one-third. Notably, even after stopping the medication, most GLP-1 users maintained their new dietary habits—"once formed, new habits largely persist."
JPMorgan data indicates that the overall net performance of the U.S. restaurant sector continues to decline, with the long/short ratio hitting multi-year lows, placing it in the first percentile.
The alcohol industry is also facing significant challenges. The stock of tequila brand Cuervo has fallen roughly 70% over the past five years, with enterprise value evaporating over 70% since 2021. Diageo also shows a clear downward trend, having lost approximately $50 billion in market value.
Additionally, the processed foods sector is listed among the potential casualties of the GLP-1 wave.
Comments